Clinical Neurology and Neurosurgery 2009-01-01

Justification of vigabatrin administration in West syndrome patients? Warranting a re-consideration for improvement in their quality of life

Harinder Jaseja

Index: Clin. Neurol. Neurosurg. 111(2) , 111-4, (2009)

Full Text: HTML

Abstract

West syndrome (WS) or infantile spasms (IS) is a severe epileptic syndrome associated with poor prognosis and increased morbidity. The exact etio-pathogenesis of the disorder still remains elusive ant therefore the management continues to pose a challenge to the clinicians. Currently, adreno-corticotrophic hormone (ACTH), steroids and vigabatrin (VGB) form the mainstay of its treatment. However, the recent detection of an irreversible visual field defect observed in as high as 30–50% of children treated with vigabatrin has raised concern over the drug’s usage. This brief paper is intended to highlight the significance of the irreversible visual toxicity in an already existent mentally challenged state in WS patients, which can lead to a worsening in the disability status of such patients. Therefore, based on the enhancement of handicap by VGB administration it is recommended that a comprehensive review be performed on its continuation in WS patients in order to prevent further deterioration of their quality of life (QOL).


Related Compounds

Related Articles:

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.

2010-01-01

[Chem. Res. Toxicol. 23 , 171-83, (2010)]

Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

2011-12-01

[J. Sci. Ind. Res. 65(10) , 808, (2006)]

Chemical genetics reveals a complex functional ground state of neural stem cells.

2007-05-01

[Nat. Chem. Biol. 3(5) , 268-273, (2007)]

Neural computational prediction of oral drug absorption based on CODES 2D descriptors.

2010-03-01

[Eur. J. Med. Chem. 45 , 930-40, (2010)]

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

2010-12-15

[Bioorg. Med. Chem. Lett. 20 , 7312-6, (2010)]

More Articles...